Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN<sup>®</sup> System Comprehensive Approach
Drug–drug interactions (DDIs) can affect both treatment efficacy and toxicity. We used Drug-PIN<sup>®</sup> (Personalized Interactions Network) software in colorectal cancer (CRC) patients to evaluate drug–drug–gene interactions (DDGIs), defined as the combination of DDIs and individual...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-01-01
|
| Series: | Pharmaceuticals |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1424-8247/14/1/67 |
| _version_ | 1797411027489390592 |
|---|---|
| author | Michela Roberto Alessandro Rossi Martina Panebianco Leda Marina Pomes Giulia Arrivi Debora Ierinò Maurizio Simmaco Paolo Marchetti Federica Mazzuca |
| author_facet | Michela Roberto Alessandro Rossi Martina Panebianco Leda Marina Pomes Giulia Arrivi Debora Ierinò Maurizio Simmaco Paolo Marchetti Federica Mazzuca |
| author_sort | Michela Roberto |
| collection | DOAJ |
| description | Drug–drug interactions (DDIs) can affect both treatment efficacy and toxicity. We used Drug-PIN<sup>®</sup> (Personalized Interactions Network) software in colorectal cancer (CRC) patients to evaluate drug–drug–gene interactions (DDGIs), defined as the combination of DDIs and individual genetic polymorphisms. Inclusion criteria were: (i) stage II-IV CRC; (ii) ECOG PS (Performance status sec. Eastern coperative oncology group) ≤2; (iii) ≥5 concomitant drugs; and (iv) adequate renal, hepatic, and bone marrow function. The Drug-PIN<sup>®</sup> system analyzes interactions between active and/or pro-drug forms by integrating biochemical, demographic, and genomic data from 110 SNPs. We selected DDI, DrugPin1, and DrugPin2 scores, resulting from concomitant medication interactions, concomitant medications, and SNP profiles, and DrugPin1 added to chemotherapy drugs, respectively. Thirty-four patients, taking a median of seven concomitant medications, were included. The median DrugPin1 and DrugPin2 scores were 42.6 and 77.7, respectively. In 13 patients, the DrugPin2 score was two-fold higher than the DrugPin1 score, with 7 (54%) of these patients experiencing severe toxicity that required hospitalization. On chi-squared testing for any toxicity, a doubled DrugPin2 score (<i>p</i> = 0.001) was significantly related to G3–G4 toxicity. Drug-PIN<sup>®</sup> software may prevent severe adverse events, decrease hospitalizations, and improve survival in cancer patients. |
| first_indexed | 2024-03-09T04:39:02Z |
| format | Article |
| id | doaj.art-641f7d587adb449089673bcdbb7412dd |
| institution | Directory Open Access Journal |
| issn | 1424-8247 |
| language | English |
| last_indexed | 2024-03-09T04:39:02Z |
| publishDate | 2021-01-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceuticals |
| spelling | doaj.art-641f7d587adb449089673bcdbb7412dd2023-12-03T13:24:13ZengMDPI AGPharmaceuticals1424-82472021-01-011416710.3390/ph14010067Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN<sup>®</sup> System Comprehensive ApproachMichela Roberto0Alessandro Rossi1Martina Panebianco2Leda Marina Pomes3Giulia Arrivi4Debora Ierinò5Maurizio Simmaco6Paolo Marchetti7Federica Mazzuca8Oncology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, University “La Sapienza”, 00187 Rome, ItalyOncology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, University “La Sapienza”, 00187 Rome, ItalyOncology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, University “La Sapienza”, 00187 Rome, ItalyDepartment of Neuroscience, Mental Health, 00187 Rome, ItalyOncology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, University “La Sapienza”, 00187 Rome, ItalyOncology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, University “La Sapienza”, 00187 Rome, ItalyDepartment of Neuroscience, Mental Health, 00187 Rome, ItalyOncology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, University “La Sapienza”, 00187 Rome, ItalyOncology Unit, Department of Clinical and Molecular Medicine, Sant’Andrea Hospital, University “La Sapienza”, 00187 Rome, ItalyDrug–drug interactions (DDIs) can affect both treatment efficacy and toxicity. We used Drug-PIN<sup>®</sup> (Personalized Interactions Network) software in colorectal cancer (CRC) patients to evaluate drug–drug–gene interactions (DDGIs), defined as the combination of DDIs and individual genetic polymorphisms. Inclusion criteria were: (i) stage II-IV CRC; (ii) ECOG PS (Performance status sec. Eastern coperative oncology group) ≤2; (iii) ≥5 concomitant drugs; and (iv) adequate renal, hepatic, and bone marrow function. The Drug-PIN<sup>®</sup> system analyzes interactions between active and/or pro-drug forms by integrating biochemical, demographic, and genomic data from 110 SNPs. We selected DDI, DrugPin1, and DrugPin2 scores, resulting from concomitant medication interactions, concomitant medications, and SNP profiles, and DrugPin1 added to chemotherapy drugs, respectively. Thirty-four patients, taking a median of seven concomitant medications, were included. The median DrugPin1 and DrugPin2 scores were 42.6 and 77.7, respectively. In 13 patients, the DrugPin2 score was two-fold higher than the DrugPin1 score, with 7 (54%) of these patients experiencing severe toxicity that required hospitalization. On chi-squared testing for any toxicity, a doubled DrugPin2 score (<i>p</i> = 0.001) was significantly related to G3–G4 toxicity. Drug-PIN<sup>®</sup> software may prevent severe adverse events, decrease hospitalizations, and improve survival in cancer patients.https://www.mdpi.com/1424-8247/14/1/67advanced colorectal cancerpharmacogenomicdrug–drug–gene interactionDrug-PIN<sup>®</sup> |
| spellingShingle | Michela Roberto Alessandro Rossi Martina Panebianco Leda Marina Pomes Giulia Arrivi Debora Ierinò Maurizio Simmaco Paolo Marchetti Federica Mazzuca Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN<sup>®</sup> System Comprehensive Approach Pharmaceuticals advanced colorectal cancer pharmacogenomic drug–drug–gene interaction Drug-PIN<sup>®</sup> |
| title | Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN<sup>®</sup> System Comprehensive Approach |
| title_full | Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN<sup>®</sup> System Comprehensive Approach |
| title_fullStr | Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN<sup>®</sup> System Comprehensive Approach |
| title_full_unstemmed | Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN<sup>®</sup> System Comprehensive Approach |
| title_short | Drug–Drug Interactions and Pharmacogenomic Evaluation in Colorectal Cancer Patients: The New Drug-PIN<sup>®</sup> System Comprehensive Approach |
| title_sort | drug drug interactions and pharmacogenomic evaluation in colorectal cancer patients the new drug pin sup r sup system comprehensive approach |
| topic | advanced colorectal cancer pharmacogenomic drug–drug–gene interaction Drug-PIN<sup>®</sup> |
| url | https://www.mdpi.com/1424-8247/14/1/67 |
| work_keys_str_mv | AT michelaroberto drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach AT alessandrorossi drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach AT martinapanebianco drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach AT ledamarinapomes drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach AT giuliaarrivi drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach AT deboraierino drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach AT mauriziosimmaco drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach AT paolomarchetti drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach AT federicamazzuca drugdruginteractionsandpharmacogenomicevaluationincolorectalcancerpatientsthenewdrugpinsupsupsystemcomprehensiveapproach |